![Kathleen Gallagher](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathleen Gallagher
Inga fler pågående positioner
Profil
Kathleen Gallagher is President, Chief Executive Officer & Director at Atrium Therapeutics, Inc. since 2026.
Formerly, Ms. Gallagher was Head-Communications at Merrimack Pharmaceuticals, Inc. from 2003 to 2016 and held the position of VP-Investor Relations & Corporate Communications at Akcea Therapeutics, Inc. Education includes undergraduate studies at Boston University.
Aktiva positioner av Kathleen Gallagher
| Företag | Position | Start |
|---|
Tidigare kända positioner av Kathleen Gallagher
| Företag | Position | Slut |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Investor Relations Kontakt | - |
| MERRIMACK PHARMACEUTICALS | Offentlig kommunikationskontakt | 2016-10-01 |
| AKCEA THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Kathleen Gallaghers utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
54
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Avidity Biosciences, Inc.
 Avidity Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that provides research and development, administrative & investment services | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
